NYSE:AVNS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. More Details


Snowflake Analysis

Adequate balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Avanos Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVNS is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: AVNS's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-0.2%

AVNS

-0.4%

US Medical Equipment

0.6%

US Market


1 Year Return

44.4%

AVNS

20.5%

US Medical Equipment

21.0%

US Market

Return vs Industry: AVNS exceeded the US Medical Equipment industry which returned 20.5% over the past year.

Return vs Market: AVNS exceeded the US Market which returned 21% over the past year.


Shareholder returns

AVNSIndustryMarket
7 Day-0.2%-0.4%0.6%
30 Day1.3%4.9%4.2%
90 Day27.1%7.4%12.4%
1 Year44.4%44.4%21.5%20.5%23.7%21.0%
3 Year1.3%1.3%73.2%68.8%47.4%37.6%
5 Year99.6%99.6%172.9%152.4%131.6%105.9%

Long-Term Price Volatility Vs. Market

How volatile is Avanos Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Avanos Medical undervalued compared to its fair value and its price relative to the market?

0.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AVNS ($48.47) is trading below our estimate of fair value ($48.57)

Significantly Below Fair Value: AVNS is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: AVNS is poor value based on its PE Ratio (166.5x) compared to the US Medical Equipment industry average (54.1x).

PE vs Market: AVNS is poor value based on its PE Ratio (166.5x) compared to the US market (21.3x).


Price to Earnings Growth Ratio

PEG Ratio: AVNS is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: AVNS is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Avanos Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

78.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVNS's forecast earnings growth (78.1% per year) is above the savings rate (2%).

Earnings vs Market: AVNS's earnings (78.1% per year) are forecast to grow faster than the US market (21.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AVNS's revenue (4.7% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: AVNS's revenue (4.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVNS's Return on Equity is forecast to be low in 3 years time (5.3%).


Next Steps

Past Performance

How has Avanos Medical performed over the past 5 years?

60.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVNS has a large one-off loss of $17.2M impacting its September 30 2020 financial results.

Growing Profit Margin: AVNS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AVNS has become profitable over the past 5 years, growing earnings by 60.2% per year.

Accelerating Growth: AVNS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AVNS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).


Return on Equity

High ROE: AVNS's Return on Equity (1.1%) is considered low.


Next Steps

Financial Health

How is Avanos Medical's financial position?


Financial Position Analysis

Short Term Liabilities: AVNS's short term assets ($567.6M) exceed its short term liabilities ($179.4M).

Long Term Liabilities: AVNS's short term assets ($567.6M) exceed its long term liabilities ($329.8M).


Debt to Equity History and Analysis

Debt Level: AVNS's debt to equity ratio (19.3%) is considered satisfactory.

Reducing Debt: AVNS's debt to equity ratio has reduced from 56.2% to 19.3% over the past 5 years.

Debt Coverage: AVNS's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: AVNS's interest payments on its debt are not well covered by EBIT (0.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Avanos Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVNS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVNS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Joe Woody (54 yo)

3.58yrs

Tenure

US$5,023,674

Compensation

Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Avanos Medical, Inc. (formerly known as Halyard Health, Inc.) since June 26, 2017. Mr. Woody served as the Chief Exe...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD5.02M) is above average for companies of similar size in the US market ($USD3.85M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Woody
CEO & Director3.58yrsUS$5.02m0.049%
$ 1.1m
Warren MacHan
Senior Vice President of Business Strategy1yrUS$911.19k0.081%
$ 1.9m
Arjun Sarker
Senior Vice President of International2.75yrsUS$836.80k0.027%
$ 633.6k
David Ball
Senior Vice President of Global Supply Chain & Procurement2.08yrsUS$1.04m0%
$ 0
Michael Greiner
Senior VP & CFO1yrno data0%
$ 0
Renato Negro
VP, Controller & Chief Accounting Officerno datano data0.049%
$ 1.1m
David Crawford
VP of FP&A and Investor Relations and Treasurerno datano datano data
S. Mansbach
Senior VP0.25yrno datano data
Michelle Scharfenberg
Senior VP and Chief Ethics & Compliance Officer0.33yrno datano data
Rhonda Gibby
Senior VP & Chief Human Resources Officer6.25yrsUS$1.03mno data
Lee Burnes
Senior Vice President of Global R&Dno datano datano data
William Haydon
Senior VP & GM of Pain Franchise0.42yrno datano data

1.0yrs

Average Tenure

54yo

Average Age

Experienced Management: AVNS's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Joseph Woody
CEO & Director3.58yrsUS$5.02m0.049%
$ 1.1m
John Byrnes
Independent Director6.25yrsUS$250.00k0.061%
$ 1.4m
William Hawkins
Independent Director5.08yrsUS$265.00k0.066%
$ 1.5m
Heidi Fields
Independent Director6.25yrsUS$270.00k0.061%
$ 1.4m
Patrick O'Leary
Independent Director6.25yrsUS$250.00k0.061%
$ 1.4m
Gary Blackford
Independent Chairman0.67yrUS$265.00k0.082%
$ 1.9m
Julie Shimer
Independent Director6.25yrsUS$265.00k0.061%
$ 1.4m
Maria Sainz
Independent Director5.92yrsUS$250.00k0.059%
$ 1.4m
Heidi Kunz
Director0.75yrno datano data

5.9yrs

Average Tenure

63yo

Average Age

Experienced Board: AVNS's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Avanos Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Avanos Medical, Inc.
  • Ticker: AVNS
  • Exchange: NYSE
  • Founded: 2014
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.305b
  • Shares outstanding: 47.55m
  • Website: https://avanos.com

Number of Employees


Location

  • Avanos Medical, Inc.
  • 5405 Windward Parkway
  • Suite 100 South
  • Alpharetta
  • Georgia
  • 30004
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVNSNYSE (New York Stock Exchange)YesCommon StockUSUSDOct 2014
8HHDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/15 00:49
End of Day Share Price2021/01/14 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.